Detail akcie Precipio Rg online

Business Summary: Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Precipio Inc revenues increased 33% to $17.4M. Net loss decreased 77% to $889K. Revenues reflect Medicare segment increase of 57% to $7M, Third party payers segment increase of 23% to $8.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$2.71 to -$0.59.